肾功能不全增加利奈唑胺相关血小板减少风险:系统评价与Meta分析
该系统评价与Meta分析纳入24项研究共3580例患者,评估肾功能与利奈唑胺诱导血小板减少症(LIT)的关联。结果显示肾功能不全患者LIT风险显著升高(未调整OR 3.54,95%CI 2.27-5.54;调整后OR 2.51,95%CI 1.82-3.45),严重肾功能不全和血液透析患者风险更高。建议对肾功能不全患者考虑减量并治疗药物监测指导。
要点
- 肾功能不全患者LIT风险约为非肾功能不全者的2.5倍(调整后OR 2.51)。
- 严重肾功能不全和血液透析患者LIT风险进一步显著升高。
- 肾功能不全患者可考虑利奈唑胺减量,并以治疗药物监测指导。
核心结论
- 肾功能不全是利奈唑胺诱导血小板减少症(LIT)的独立危险因素,调整后OR为2.51(95%CI 1.82-3.45)。
研究设计与样本
- 系统评价与Meta分析,检索PubMed、EMBASE和Cochrane Library自建库至2021年2月,纳入24项研究共3580例患者。
- 采用随机效应模型分别计算未调整和调整后的OR及95%CI。
主要发现
- 肾功能不全(RI)患者较非RI患者LIT风险升高:未调整OR 3.54(95%CI 2.27-5.54;I²=77.7%),调整后OR 2.51(95%CI 1.82-3.45;I²=17.9%)。
- 固定常规剂量(600 mg每12小时)亚组及按种族、样本量、研究质量的亚组分析中关联持续存在。
- 严重RI和血液透析患者LIT风险显著高于无严重RI和无血液透析患者。
- LIT患者eGFR和Ccr显著低于非LIT患者。
关键数值与推荐
- 肾功能不全患者LIT风险升高,调整后OR 2.51(95%CI 1.82-3.45)。
- 常规剂量600 mg每12小时亚组中关联仍存在。
临床怎么用
- 对肾功能不全患者应警惕LIT风险,加强血小板监测。
- 对治疗失败风险低的肾功能不全患者可考虑减少利奈唑胺剂量。
- 减量决策最好以治疗药物监测(TDM)为指导。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The association of renal function and linezolid-induced thrombocytopaenia (LIT) remains controversial. We performed a meta-analysis to determine whether impaired renal function is associated with an increased LIT risk. METHODS: We conducted a systematic search of PubMed, EMBASE and the Cochrane Library from inception to February 2021 for eligible studies evaluating the relationship between renal function and LIT. Indicators of renal function included renal impairment (RI), severe RI, haemodialysis status, creatinine clearance rate (Ccr) and estimated glomerular filtration rate (eGFR). Unadjusted and adjusted estimates and 95% confidence intervals (CIs) were calculated separately using a random-effect model. RESULTS: A total of 24 studies with 3580 patients were included in the meta-analysis. RI patients had an increased LIT risk compared to non-RI patients in both the unadjusted (OR 3.54; 95% CI 2.27, 5.54; I2 = 77.7%) and adjusted analyses (OR 2.51; 95% CI 1.82, 3.45; I2 = 17.9%). This association persisted in the subset of studies involving only patients receiving a fixed conventional dose (600 mg every 12 h) and other subgroup analyses by ethnicity, sample size and study quality. Moreover, the LIT risk was significantly higher in patients with severe RI and haemodialysis than in patients without severe RI and haemodialysis. The eGFR and Ccr were significantly lower in LIT patients than in non-LIT patients. CONCLUSIONS: Impaired renal function is associated with an increased risk of LIT. A reduced linezolid dose may be considered in RI patients at a low risk of treatment failure, ideally guided by therapeutic drug monitoring.
引用
- Shi C, Xia J, Ye J, et al. Effect of renal function on the risk of thrombocytopaenia in patients receiving linezolid therapy: A systematic review and meta-analysis. Br J Clin Pharmacol. 2021. PMID: 34192814. doi:10.1111/bcp.14965
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。